Definitive Contract HHSO100200600013C
Award Date 5/1/06
Potential Completion Date 1/30/12
Potential Value $235M
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Cost Plus Fixed Fee
Place of Performance
Frederick, MD 21702, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
8
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This is a $1,159,290,240.64 cost-plus-award-fee contract awarded by the Department of the Army Medical Command to Dynport Vaccine Company LLC, a subsidiary of General Dynamics Corp. The contract, which has no set-aside designation, is for research, development, manufacturing, and testing services to support biopharmaceutical products targeting infectious diseases. Dynport has provided similar services under past federal contracts with NIH, HHS, and the Joint Program Executive Office for...
- This contract award was issued by the Department of Health and Human Services, National Institutes of Health, National Institute of Allergy and Infectious Diseases to Dynport Vaccine Company LLC, a subsidiary of General Dynamics Corp. The $136,259.00 award is a delivery order under the Therapeutics Against Infectious Diseases Phase 1 contract, which funds a Phase 1 clinical trial unit for therapeutics against infectious diseases. The contract type is cost plus fixed fee, and there is no...
- This is a federal contract award from the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Dynport Vaccine Company LLC, a subsidiary of General Dynamics Corp. The $129,318.29 contract is a cost-plus-fixed-fee delivery order under the "Therapeutics Against Infectious Diseases Phase 1" contract vehicle, which funds Phase 1 clinical trials for infectious disease therapeutics. Dynport will provide a range of services including preclinical development,...
- This is a cost-plus-fixed-fee delivery order awarded by the Medical Command (MEDCOM) of the U.S. Army to Dynport Vaccine Company LLC, a subsidiary of General Dynamics Corporation. The $1,685,156.08 contract is for the Phase 2 clinical trial of the Comprehensive Preventive and Preparedness (CPP) program, which develops medical countermeasures for infectious diseases. The contract is part of Dynport's existing $30 million Preclinical Services for Biopharmaceutical Product Development indefinite...
- This federal contract award to Dynport Vaccine Company LLC, a subsidiary of General Dynamics Corp, is in support of a Phase 1 Clinical Trial Unit for Therapeutics Against Infectious Diseases. The $1,757,807.36 ceiling value contract was awarded on August 19, 2016 by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services. The contract is a delivery order against the $30 million Preclinical Services for Biopharmaceutical...
- This is a federal contract award with a potential value of $139,426.00, issued by the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to Dynport Vaccine Company LLC, a subsidiary of General Dynamics Corp. The contract is a Delivery Order under the "Therapeutics Against Infectious Diseases Phase 1" master IDIQ contract. The award is for a PHASE 1 CLINICAL TRIAL UNIT FOR THERAPEUTICS AGAINST...
- This federal contract award was issued by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Dynport Vaccine Company LLC, a subsidiary of General Dynamics Corp. The $222,661 award is a delivery order under the Therapeutics Against Infectious Diseases Phase 1 IDIQ contract, which funds Phase 1 clinical trials for therapeutics against infectious diseases. The contract does not have a set-aside designation. This order is for Dynport to conduct Phase 1...
- The National Institute of Allergy and Infectious Diseases awarded a definitive contract to Dynport Vaccine Company LLC for a Phase 1 Clinical Trial Unit for Therapeutics Against Infectious Diseases on May 30, 2008, with a ceiling value of $35.6 million and ultimate completion date of June 17, 2019. The contract employs cost plus fixed fee pricing. Work is performed in Frederick, MD. The solicitation describes establishment and operation of a clinical trial unit to support Phase 1 trials of...
- This is a $2,265,501.00 delivery order contract awarded to Dynport Vaccine Company LLC, a subsidiary of General Dynamics Corporation, by the National Institute of Allergy and Infectious Diseases (NIAID) under the Early Phase Clinical Trial Units (EPCTU) IDIQ contract vehicle. The contract is for cost plus fixed fee services to support early phase clinical trials, with a period of performance through July 15, 2025. The contract does not have a set-aside designation. Dynport Vaccine Company has...
- This is a $3,026,999.00 firm fixed price contract awarded by the Department of Health and Human Services' National Institutes of Health (NIH) to Dynport Vaccine Company LLC, a subsidiary of General Dynamics Corporation, for the development of a recombinant Type E botulinum neurotoxin vaccine. The contract has a completion date of September 29, 2006 and does not use a set-aside designation. Dynport Vaccine Company LLC is a limited liability company that provides research, development,...